Japer Therapeutics Warrants
JSPRW
6 hedge funds and large institutions have $383K invested in Japer Therapeutics Warrants in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
197% more capital invested
Capital invested by funds: $129K → $383K (+$254K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
14.44% more ownership
Funds ownership: 6.07% → 20.51% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$232K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$133 |
JSPRW Hedge Fund Activity: Q2 2025 in Review
6 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2025, worth a combined $383K — up 197% from $129K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new JSPRW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $232K. The largest seller was UBS Group, exiting entirely with an estimated $133 sold.
- 6 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2025, up from 5 in Q1 2025.
- Funds reported $383K of Japer Therapeutics Warrants stock for Q2 2025, up 197% quarter-over-quarter.
- 2 funds opened new Japer Therapeutics Warrants positions in Q2 2025 and 1 closed out, a net change of +1 holder.
- The largest Japer Therapeutics Warrants buyer in Q2 2025 was Toronto Dominion Bank, an estimated $232K added.
- The largest Japer Therapeutics Warrants seller in Q2 2025 was UBS Group, an estimated $133 sold.
Based on aggregated 13F filings for Q2 2025.